Treatment for hepatitis C virus in human immu- nodeficiency virus-infected patients: clinical ben- efits and cost-effectiveness. Arch Intern Med 2002; 162:2545-56.Kuehne, F.C., et al., Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and ...
(2004). Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology, 39 , 880–890.Gao B, Hong F, Radaeva S. Host factors and failure of interferon-α treatment in hepatitis C virus. Hepatology. 2004; 39 (4):880–890. doi: 10.1002/hep.20139. [ Cross ...
Hepatitis C virus (HCV) infection is curable. Hep C treatment is easier and shorter than ever before and the vast majority of those who took the newest medications were cured.
Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population. Methods We used 3-year follow-up data from the HEPAVIH ANRS-CO13 nationwide French cohort which...
The experience of hepatitis C treatment for people with a history of mental health problems: An interpretative phenomenological analysis. This qualitative study explores the experience of hepatitis C virus treatment for people with pre-existing mental health problems within a large city hospi... K,War...
Interferon-Free Treatment for Chronic Hepatitis C in Japan: Prevention of Liver Fibrosis, Liver Cirrhosis and Hepatocellular Carcinoma Progress in interferon-free treatment against hepatitis C virus (HCV) has remained a challenge in patients with decompensated cirrhosis due to a paucity of... T Kanda...
Reduce the amount of hep B virus in your body Reduce the risk of developing serious liver problems It’s important to see your doctor regularly so he or she can manage your treatment progress. When you take medicine for your chronic hep B, sometimes you may have side effects. Sometimes, ...
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University. Data presented today demonstrate that there are considerable restrictions in the reimbursement of direct-acting antiviral (DAA) th...
In the first study, previously untreated patients with chronic hepatitis C were randomly assigned after stratification for HCV genotype to either RBV combined with PegIFNα2a or PegIFNα2b for 24 or 48 weeks, according to virus genotype. Researchers found that overall, the SVR rate was significan...
摘要: Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon- and ribavirin, the consequences of treatment failure, and possible means of optimizing future therapies that use DAAs. (HEPATOLOGY 2011;)...